+ Filter
Loading...
ERBB2 & CD3
Loading...Anti-ERBB2 & CD3 Products
-
- Derivation: Humanized (from mouse)
- Species Reactivity: Human
- Type: IgG1 - kappa
- Application: FC, IP, ELISA, Neut, FuncS, IF, IHC
- Anti-ERBB2 immunotoxin 4D5 (scFv)-DT (AGTO-G022D)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
- Mouse Anti-CD3 Recombinant Antibody (TAB-0416CL) (TAB-0416CL)
-
- Application: FC, IB, ELISA
-
- Derivation: Chimeric (Human/Mouse)
- Species Reactivity: Human
- Type: IgG1 - kappa
- Application: IF, IP, Neut, FuncS, ELISA, FC, WB
-
- Derivation: Humanized (from mouse)
- Species Reactivity: Human
- Type: IgG1 - kappa
- Application: FuncS, IF, Neut, ELISA, FC, IP, WB
-
- Species Reactivity: Human
- Type: Mouse IgG
- Application: ELISA, WB, FC
- Humanized Anti-Human CD3 Recombinant Antibody (TAB-0418CL)
-
- Type: Humanized Antibody
- Application: ELISA, FC, FuncS
- Human Anti-ERBB2 Recombinant Antibody; scFv Fragment (TAB-0191CL-S(P)) (TAB-0191CL-S(P))
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA, Cyt, Internalization
-
- Derivation: Humanized (from mouse)
- Species Reactivity: Human
- Type: IgG1 - kappa
- Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
-
- Derivation: Humanized
- Species Reactivity: Human
- Type: Fab fragment
- Application: ELISA
- Rat Anti-CD3 Recombinant Antibody (clone 17A2) (MOB-0202MC)
-
- Species Reactivity: Mouse
- Type: Rat IgG2b, κ
- Application: FC, IHC, IP, Activ, CMCD, Depletion
- Human Anti-ERBB2 Recombinant Antibody; Fab Fragment (TAB-033CT-F(E)) (TAB-033CT-F(E))
-
- Derivation: Humanized
- Species Reactivity: Human
- Type: Humanized Fab
- Application: ELISA, WB
-
- Derivation: Human
- Species Reactivity: Human
- Type: Llama VHH
- Application: SPR
-
- Derivation: Human
- Species Reactivity: Human
- Type: Llama VHH
- Application: SPR
-
- Derivation: Humanized
- Species Reactivity: Human
- Type: Llama VHH
- Application: ELISA
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL15
- Host: Mouse
- Cytokine 1 Species: Human
- Molecule Class: IgG-IL15
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL15
- Host: Mouse
- Cytokine 1 Species: Human
- Molecule Class: scFv-IL15
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: GM-CSF
- Host: Human
- Cytokine 1 Species: Human
- Molecule Class: IgG3-GM-CSF
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IFNα
- Host: Human
- Cytokine 1 Species: Mouse
- Molecule Class: IgG3-IFNα
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL15
- Cytokine 2: L22
- Host: Human
- Cytokine 1 Species: Human
- Cytokine 2 Species: Human
- Molecule Class: IL15-L22-scFv
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL15
- Cytokine 2: L22
- Host: Human
- Cytokine 1 Species: Human
- Cytokine 2 Species: Human
- Molecule Class: L kappa; IL15-L22-IgG1
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: RLI
- Cytokine 2: L22
- Host: Human
- Cytokine 1 Species: Human
- Cytokine 2 Species: Human
- Molecule Class: RLI-L22-scFv
- Anti-ERBB2 immunotoxin 4D5 (scFv)-PE (AGTO-G022E)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
-
- Species Reactivity: Human
- Type: Llama VHH
- Application: IHC, FC, CA, FuncS
-
- Species Reactivity: Human
- Type: Mouse Fab
- Application: ELISA, WB, FC
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: RLI
- Host: Human
- Cytokine 1 Species: Human
- Molecule Class: RLI-scFv
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: RLI
- Host: Human
- Cytokine 1 Species: Human
- Molecule Class: RLI-IgG1
-
- Target: HER2/neu
- Species Reactivity: Human
- Cytokine 1: IL2
- Host: Humanized from Mouse
- Cytokine 1 Species: Human
- Molecule Class: scFv‑Fc‑IL2
-
- Species Reactivity: Human
- Type: Human Fab
- Application: WB
-
- Species Reactivity: Human
- Type: Human scFv
- Application: WB
- Anti-Mouse CD3 Recombinant Antibody (Dow2) (TAB-0365CL)
-
- Application: FC, IHC
- Mouse Anti-CD3 Recombinant Antibody (TAB-0422CL) (TAB-0422CL)
-
- Species Reactivity: Human, Cynomolgus monkey
- Type: Mouse IgG
- Application: ELISA
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA, WB, FuncS
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA, WB, FuncS
- Anti-ERBB2 immunotoxin 4D5 (scFv)-Gel (AGTO-G022G)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
- Anti-ERBB2 immunotoxin 4D5 (scFv)-RTA (AGTO-G022R)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
- Anti-ERBB2 immunotoxin 4D5 (scFv)-Sap (AGTO-G022S)
-
- Species Reactivity: Human
- Application: Cytotoxicity assay, Function study
-
- Scaffold Name: 2-Helix small protein
- Target: HER2
- Species Reactivity: Human
- Derivation: Phage display
- Aptide scaffold protein anti-Human HER2 (SAP-L048)
-
- Scaffold Name: Aptide
- Target: HER2
- Species Reactivity: Human
- Derivation: Phage display
- Anti-HER2 (trastuzumab)-SSNPP-DM3 ADC (ADC-136LCT)
-
- Target: HER2
- Linker: SSNPP
- Drug: DM3
- Anti-HER2 (trastuzumab)-SSNPP-DM4 ADC (ADC-137LCT)
-
- Target: HER2
- Linker: SSNPP
- Drug: DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
- Anti-HER2 (trastuzumab)-auristatin ADC (ADC-138LCT)
-
- Target: HER2
- Linker: The linker contains two ethylene glycol moieties modified with a terminal alkoxy-amine group to improve solubility and minimize export of the more hydrophilic derivatized analogs by drug pumps
- Drug: auristatin
- Anti-HER2 Fab (trastuzumab)-Porphyrin ADC (ADC-139LCT)
-
- Target: HER2
- Drug: Porphyrin
- Anti-HER2 Fab (trastuzumab)-PEG-porphyrin ADC (ADC-140LCT)
-
- Target: HER2
- Linker: PEG
- Drug: porphyrin
- Anti-HER2-SMCC-DM1 ADC (ADC-001LZY)
-
- Target: HER2
- Linker: SMCC (N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate)
- Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
- Anti-HER2 (Trastuzumab)-MC-MMAE (Thiol MMAE) ADC (ADC-103LCT)
-
- Target: HER2
- Linker: Mc (maleimidocaproyl)
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2 (Trastuzumab)-AO-MC-MMAE (Glyco MMAE) ADC (ADC-104LCT)
-
- Target: HER2
- Linker: AO-Mc-
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2 (trastuzumab) Fab-bisAlk-vc-MMAE ADC (ADC-122LCT)
-
- Target: HER2
- Linker: bisAlk-VC
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2 (trastuzumab)-bisAlk-vc-MMAE ADC (ADC-123LCT)
-
- Target: HER2
- Linker: bisAlk-VC
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2 (Trastuzumab)-CC-MMAD ADC (ADC-126LCT)
-
- Target: HER2
- Linker: CC
- Drug: MMAD (monomethyl auristatin D)
- Anti-HER2 (Trastuzumab)-mc-MMAD ADC (ADC-127LCT)
-
- Target: HER2
- Linker: Mc (maleimidocaproyl)
- Drug: MMAD (monomethyl auristatin D)
- Anti-HER2 (trastuzumab)-mc-c-term-Dol15 ADC (ADC-128LCT)
-
- Target: HER2
- Linker: Mc (maleimidocaproyl)
- Drug: dolastatin 15 derivatives (Dol15)
- Anti-HER2 (trastuzumab)-mcc-DM1 ADC (ADC-129LCT)
-
- Target: HER2
- Linker: mcc (Maleimidomethyl cyclohexane-1-carboxylate)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- thio-Anti-HER2 (trastuzumab)-mpeo-DM1 ADC (ADC-130LCT)
-
- Target: HER2
- Linker: mpeo
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2 (trastuzumab)-NGM-doxorubicin ADC (ADC-131LCT)
-
- Target: HER2
- Linker: NGM
- Drug: doxorubicin
- Anti-HER2-MT-vc-MMAE ADC (ADC-251CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-MT-vc-MMAE ADC (ADC-252CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-MT-vc-MMAE ADC (ADC-253CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-MT-vc-MMAE ADC (ADC-254CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-MP(T-vc)-MMAE ADC (ADC-255CL)
-
- Target: HER2
- Linker: MP(T-VC)
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino) phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-MC-vc-PABC-MMAE ADC (ADC-256CL)
-
- Target: HER2
- Linker: MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Drug: (S,E)-N-(4-(aminomethyl)benzylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-MT-vc-MMAE ADC (ADC-257CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2-MT-vc-MMAE ADC (ADC-258CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Recombinant Anti-human ERBB2 Intrabody [(D-Arg)9] (IAB-B008(A))
-
- Species Reactivity: human
- Type: scFv-(D-Arg)9
- Application: IF, FC, FuncS
- Recombinant Anti-human ERBB2 Intrabody [+36 GFP] (IAB-B008(G))
-
- Species Reactivity: human
- Type: scFv-(+36GFP)
- Application: WB, ICC, FuncS
- Recombinant Anti-human ERBB2 Intrabody [Tat] (IAB-B008(T))
-
- Species Reactivity: human
- Type: scFv-Tat
- Application: ICC, Neut, FuncS
- Anti-Her-2 receptor-Phor18 molecules ADC (ADC-132CL)
-
- Target: Her-2 receptor
- Linker: 2, 4 or 6 Phor18 molecules
- Anti-Her2-ALKYNE-MMAF ADC (ADC-209CL)
-
- Target: Her2
- Linker: ALKYNE
- Drug: MMAF (Monomethyl auristatin F)
- Anti-Her2-VCP-cyclooctyne-MMAF ADC (ADC-210CL)
-
- Target: Her2
- Linker: valine-citruline-p-amino-benzoyl-carbonate (VCP)-cyclooctyne
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2-MT-vc-MMAE ADC (ADC-248CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
-
- Target: HER2
- Linker: hydroxyl amino PEG linker
- Drug: MMAD (monomethyl auristatin D)
- Anti-HER2-MT-vc-MMAE ADC (ADC-249CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
-
- Target: HER2
- Linker: thioether SMCC linker
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2-MT-vc-MMAE ADC (ADC-250CL)
-
- Target: HER2
- Linker: MT-VC
- Drug: (S,E)-N-(4-aminophenylsulfonyl)-2,5-dimethyl-4-((S)-N,3,3-trimethyl-2-((S)-3-methyl-2-(methylamino)-3-phenylbutanamido)butanamido)hex-2-enamide
- Anti-HER2 (trastuzumab)-SPDP-DM1 ADC (ADC-134LCT)
-
- Target: HER2
- Linker: SPDP ( N-succinimidyl 3-(2-pyridyldithio)propionate)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
-
- Target: HER2
- Linker: MC-PEG8
- Drug: Dol10 (Thiol Dol10)
- Anti-HER2 (trastuzumab)-SPP-DM1 ADC (ADC-135LCT)
-
- Target: HER2
- Linker: SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
-
- Target: HER2
- Linker: AO-Mc-PEG8
- Drug: Dol10 (Thiol Dol10)
- Anti-HER2-NGMs-MMAE ADC (ADC-035LZY)
-
- Target: HER2
- Linker: NGMs(next generation maleimides)
- Drug: MMAE (monomethyl auristatin E)
- Anti-HER2-DBM-MMAF ADC (ADC-105LZY)
-
- Target: HER2
- Linker: DBM(dibromomaleimide)
- Drug: MMAF(monomethyl auristatin F)
- Anti-HER2-mc-MMAF ADC (ADC-107LZY)
-
- Target: HER2
- Linker: mc(maleimidocaproyl)
- Drug: MMAF(monomethyl auristatin F)
- Anti-HER2-Amberstatin (AS269) ADC (ADC-109LZY)
-
- Target: HER2
- Linker: non-natural amino acids (Ambrx' technology)
- Drug: Amberstatin (AS269)
- Anti-HER2-vandetanib ADC (ADC-068LZY)
-
- Target: HER2
- Drug: vandetanib
- Anti-HER2-DUBA-Duocarmycins ADC (ADC-069LZY)
-
- Target: HER2
- Linker: DUBA (DUocarmycinhydroxyBenzamide-Azaindole
linker) ("mc"-VC-PABC-CM) - Drug: Duocarmycins
- Anti-HER2-DOX ADC (ADC-131LZY)
-
- Target: HER2
- Linker: thiomaleamicacids-p-aminobenzyloxycarbonyl
- Drug: doxorubicin
- Anti-HER2-vc-MMAE ADC (ADC-081LZY)
-
- Target: HER2
- Linker: VC (valine-citrulline)
- Drug: MMAE(monomethyl auristatin E)
- Anti-HER2-SPP-DM1 ADC (ADC-132LZY)
-
- Target: HER2
- Linker: SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)
- Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
- Anti-HER2-vc-Duostatin-3 ADC (ADC-087LZY)
-
- Target: HER2
- Linker: VC (valine-citrulline)
- Drug: Duostatin-3
- Anti-HER2-[14C]-SMCC-DM1 ADC (ADC-150LZY)
-
- Target: HER2
- Linker: [14C]-SMCC
- Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
- Anti-Her2-saporin 6 A157C ADC (ADC-164LZY)
-
- Target: Her2
- Linker: aminooxy-maleimide linker
- Drug: saporin 6 A157C
- Anti-Her2-MCC-DM1 ADC (ADC-174LZY)
-
- Target: Her2
- Linker: MCC (Maleimidomethyl cyclohexane-1-carboxylate)
- Drug: DM1(N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine)
- Anti-Her2-mc-vc-PABC-MMAE ADC (ADC-175LZY)
-
- Target: Her2
- Linker: mc-VC-PABC (maleimidocaproyl valine-citrulline-p-aminobenzyl carbamoyl)
- Drug: MMAE (monomethyl auristatin E)
-
- Target: HER2
- Linker: vc (valine-citrulline)
- Drug: Duocarmycins
- Anti-HER2-Gly5-modified DM1 ADC (ADC-147CL)
-
- Target: HER2
- Drug: Gly5-modified DM1 (Gly5-modified N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2-vcPAB-MMAE ADC (ADC-148CL)
-
- Target: HER2
- Linker: VC-PAB (valine-citrulline-p-aminobenzoyloxycarbonyl)
- Drug: MMAE (Monomethyl auristatin E)
- Anti-HER2 (clone hu4D5Fabv8)-MC-vc-PAB-MMAF ADC (ADC-183CL)
-
- Target: HER2
- Linker: MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2 (clone hu4D5Fabv8)-MC-MMAF ADC (ADC-184CL)
-
- Target: HER2
- Linker: Mc (maleimidocaproyl)
- Drug: MMAF (Monomethyl auristatin F)
- Anti-HER2 (clone hu4D5Fabv8)-BMPEO-DM1 ADC (ADC-185CL)
-
- Target: HER2
- Linker: BMPEO (bis-maleimido-trioxyethylene glycol)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-HER2-BMPEO-DM1 ADC (ADC-186CL)
-
- Target: HER2
- Linker: BMPEO (bis-maleimido-trioxyethylene glycol)
- Drug: DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Anti-Her2-vc-[14C]MMAE ADC (ADC-221LZY)
-
- Target: Her2
- Linker: VC(valine-citrulline)
- Drug: [14C]MMAE(14C-labeled monomethyl auristatin E)
View More Products
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Background
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). It is composed of four distinct chains. In mammals, the complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains.


Bladder Cancer
Non-small Cell Lung Cancer
ErbB Signaling Pathway
